Ces Urol 2004, 8(1):25-27 | DOI: 10.48095/cccu2004007

Treatment of renal carcinoma with metastases

J. Stolz, J. Novák

Urologická klinika 1. LF UK a VFN, Praha, katedra urologie IPVZ, Praha, přednosta: prof. MUDr. J. Dvořáček, DrSc.

The approach to treatment mode and adjuvant therapy of patients with generalized carcinoma of the kidney has been reevaluated significantly in the past 20 years. Formerly unambiguously conservative treatment has been changed to active on the basis of new information from general oncology and immunology. On the basis of distinct criteria we use surgical therapy together with adjuvant administration of combined immunotherapy in selected patients.
There were 1621 patients treated for malignant kidney tumour in the urological department of the General Faculty Hospital and 1st medical Faculty in the years 1980 - 2002. Out of these, in 103 patients a metastasing carcinoma of the kidney was diagnosed primarily. The metastases were mostly localised in the lung, liver, brain and bone. 57 patients were treated with combined immunochemotherapy of interleukin-2, interferon-? a 5-fluorouracil according to Atzpodien. 46 patients were treated adjuvantly after nephrectomy, and 14 patients were treated primarily neoadjuvantly with subsequent nephrectomy. In five patients, inhalation therapy with interleukin-2 was added. We registered treatment response in 10 patients (23 %) treated adjuvantly and in 2 patients (15 %) treated neoadjuvantly. The treatment had to be ceased prematurily because of severe toxic reaction only in 3 patients (5 %). At present, immunochemotherapy represents the only effective treatment mode in patients with metastatic kidney cancer.

Keywords: metastatic kidney cancer, systemic imunochemotherapy, inhalation immunotherapy

Published: January 1, 2004